Zacks Investment Research downgraded shares of Nabriva Therapeutics AG (NASDAQ:NBRV) from a buy rating to a hold rating in a report published on Wednesday.
According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “
NBRV has been the topic of a number of other reports. Wedbush restated an outperform rating and set a $17.00 target price on shares of Nabriva Therapeutics AG in a report on Tuesday, August 9th. HC Wainwright began coverage on shares of Nabriva Therapeutics AG in a research report on Thursday, September 8th. They set a buy rating and a $16.00 price objective for the company. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $15.38.
Nabriva Therapeutics AG (NASDAQ:NBRV) traded down 5.7902% during midday trading on Wednesday, hitting $6.5099. 8,688 shares of the stock were exchanged. Nabriva Therapeutics AG has a one year low of $6.26 and a one year high of $10.69. The firm’s market capitalization is $138.38 million. The company has a 50 day moving average price of $7.42 and a 200 day moving average price of $7.85.
Nabriva Therapeutics AG (NASDAQ:NBRV) last issued its earnings results on Tuesday, August 9th. The company reported ($0.50) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($6.25) by $5.75. Equities analysts anticipate that Nabriva Therapeutics AG will post ($1.93) EPS for the current year.
A number of institutional investors have recently added to or reduced their stakes in NBRV. Jackson Park Capital LLC acquired a new stake in shares of Nabriva Therapeutics AG during the second quarter worth about $195,000. Opaleye Management Inc. boosted its stake in shares of Nabriva Therapeutics AG by 24.5% in the first quarter. Opaleye Management Inc. now owns 273,800 shares of the company’s stock worth $2,453,000 after buying an additional 53,800 shares during the last quarter. Finally, Vivo Capital LLC acquired a new stake in shares of Nabriva Therapeutics AG during the first quarter worth about $28,239,000. 63.05% of the stock is owned by hedge funds and other institutional investors.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs).